Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting

Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors (PARPi) are metabolized either via carboxylesterase (niraparib) or cytochrome P450 (CYP) enzymes (olaparib and rucaparib). Patients with advanced epithelial ovarian cancer (aOC) who receive concomitant medication metabolized by the CYP s...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Bobbie J. Rimel (Yazar), Dana M. Chase (Yazar), Jessica Perhanidis (Yazar), Armen A. Ghazarian (Yazar), Ella Xiaoyan Du (Yazar), Travis Wang (Yazar), Jinlin Song (Yazar), Amanda K. Golembesky (Yazar), Jean A. Hurteau (Yazar), Linda Kalilani (Yazar), Ritu Salani (Yazar), Bradley J. Monk (Yazar)
Materyal Türü: Kitap
Baskı/Yayın Bilgisi: Elsevier, 2024-02-01T00:00:00Z.
Konular:
Online Erişim:Connect to this object online.
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Internet

Connect to this object online.

3rd Floor Main Library

Detaylı Erişim Bilgileri 3rd Floor Main Library
Yer Numarası: A1234.567
Kopya Bilgisi 1 Kütüphanede